Skip to Content

Genomic Subtypes of AML Determines Sensitivity to NK Cell Cytotoxicity

AML is a very heterogeneous disease and in this MEDtalk, Hanna Duàn, PhD researcher from the Hematology Research Unit at the University of Helsinki, Finland, explains how genomic subtypes of AML can be a way to determine the most suitable treatment for patients.

Hanna Duàn

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top